Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Update

Entero Therapeutics, Inc. (NASDAQ:ENTO) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 295,800 shares, a growth of 233.5% from the September 30th total of 88,700 shares. Based on an average daily volume of 814,900 shares, the short-interest ratio is currently 0.4 days. Approximately 6.4% of the shares of the stock are short sold.

Entero Therapeutics Stock Performance

ENTO stock traded down $0.05 during trading on Friday, hitting $0.63. The company had a trading volume of 105,785 shares, compared to its average volume of 374,309. The company has a 50-day simple moving average of $0.43. Entero Therapeutics has a 12 month low of $0.19 and a 12 month high of $14.51. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.21 and a quick ratio of 1.21.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.